Loading...
By Joe Elia
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
Zolgensma — a gene therapy for children with spinal muscular atrophy and the world's most expensive drug at $2.1 million for one-time treatment — was approved for marketing while Novartis withheld information for months that lab data had been manipulated by a subsidiary, AveXis. The information was withheld until a month after FDA approval, according to the New York Times.
In a statement, the FDA says it "remains confident that Zolgensma should remain on the market," adding that "the totality of the evidence ... continues to provide compelling evidence supporting an overall favorable benefit-risk profile." The agency notes that "AveXis became aware of ... the data manipulation ... before the FDA approved the product, yet did not inform the FDA until after the product was approved."
Novartis' CEO told investors that "we are now in the process of exiting the small number of AveXis scientists" who were involved, according to the industry newsletter Endpoints News.
Comment
LINK(S):
New York Times story (Registration or subscription may be required)
FDA statement (Free)
Endpoints News article (Registration or subscription may be required)